Dr. Sharma on PD-L1 as Biomarker for Immunotherapy in Bladder Cancer

Padmanee Sharma, MD, PhD
Published: Friday, Feb 12, 2016



Padmanee Sharma, MD, PhD, professor of Immunology, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses PD-L1 as a predictive biomarker for immunotherapy in patients with bladder cancer.

PD-L1 as a biomarker is generating much excitement in the field of bladder cancer, as anti–PD-1/PD-L1 agents have demonstrated promise in these patients, Sharma explains.

However, Sharma cautions that PD-L1 may not be the most accurate and predictive biomarker, as it changes over time and does not present a clear picture of the evolving immune response. Other biomarkers, including CD8 T cells, CD45RA cells, and Granzyme B may be worth investigating, she adds.

SELECTED
LANGUAGE


Padmanee Sharma, MD, PhD, professor of Immunology, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses PD-L1 as a predictive biomarker for immunotherapy in patients with bladder cancer.

PD-L1 as a biomarker is generating much excitement in the field of bladder cancer, as anti–PD-1/PD-L1 agents have demonstrated promise in these patients, Sharma explains.

However, Sharma cautions that PD-L1 may not be the most accurate and predictive biomarker, as it changes over time and does not present a clear picture of the evolving immune response. Other biomarkers, including CD8 T cells, CD45RA cells, and Granzyme B may be worth investigating, she adds.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x